Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

β- d - N 4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells

5 May 2021

Abstract excerpt

Mutagenic ribonucleosides can act as broad-based antiviral agents. They are metabolized to the active ribonucleoside triphosphate form and concentrate in genomes of RNA viruses during viral replication. β-d-N4-hydroxycytidine (NHC, initial metabolite of molnupiravir) is >100-fold more active than ribavirin or favipiravir against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), with antiviral activity...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to COVID-19 Clinical Research Studies
Share to Immune responses and vaccinations
Share to SARS-CoV-2 and COVID-19 Research

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33961695
DOI: 10.1093/infdis/jiab247

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 18 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

β- d - N 4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian CellsPMID 33961695Read ↗

Human genetic risk of treatment with antiviral nucleoside analog drugs that induce lethal mutagenesis: the special case of molnupiravirSemantic proximity Read ↗

Human genetic risk of treatment with antiviral nucleoside analog drugs that induce lethal mutagenesis - the special case of molnupiravirSemantic proximity Read ↗

Comprehensive genotoxicity and carcinogenicity assessment of molnupiravirSemantic proximity Read ↗

Repurposing Molnupiravir for COVID-19: The Mechanisms of Antiviral ActivitySemantic proximity Read ↗

Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis.Semantic proximity Read ↗

Mutagenic properties of ribonucleotide analogues in reverse transcription with HIV and AMV reverse transcriptases.Semantic proximity Read ↗

Small-Molecule Antiviral β- d - N 4 -Hydroxycytidine Inhibits a Proofreading-Intact Coronavirus with a High Genetic Barrier to ResistanceSemantic proximity Read ↗

Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesisSemantic proximity Read ↗

Implications of high RNA virus mutation rates: lethal mutagenesis and the antiviral drug ribavirin.Semantic proximity Read ↗

Lethal Mutagenesis of Picornaviruses with N-6-Modified Purine Nucleoside AnaloguesSemantic proximity Read ↗

Molnupiravir Does Not Induce Mutagenesis in Host Lung Cells during SARS-CoV-2 TreatmentSemantic proximity Read ↗

Atypical Mutational Spectrum of SARS-CoV-2 Replicating in the Presence of Ribavirin.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.